CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has appointedCHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has appointed

ZOLL Medical Appoints Eric Knudsen as New CEO

4 min read

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has appointed Eric Knudsen as its new Chief Executive Officer, effective April 1. Knudsen will succeed Jon Rennert, who served as ZOLL’s CEO for the past 10 years and will assume a new role as Executive Chairman of ZOLL’s Board of Directors.

“As a global leader in medical technology, ZOLL is continually looking for ways to expand our business and reach more patients in need,” said Rennert. “Eric has played a unique role in developing our growth strategies and driving our expansion, and I am confident he will lead ZOLL to even greater growth and success.”

“I am honored to become ZOLL’s next CEO,” said Knudsen. “ZOLL has a long legacy of innovation and clinical excellence, and today our medical devices, software, and related services are used worldwide to diagnose and treat patients suffering from serious cardiopulmonary and respiratory conditions. We will continue to lead with our commitment to patients and customers and our passion for improving outcomes and helping save lives.”

Knudsen has nearly 30 years of experience in the medtech industry, with deep expertise in business development and corporate strategy. He led ZOLL’s Corporate Development team for six years and was responsible for investing in strategic relationships and acquiring more than a dozen new technologies.

For the past four years, Knudsen was President of ZOLL Itamar, a division of ZOLL that is focused on the diagnosis of sleep disorders. Knudsen led the division through significant growth and a dramatic increase in profitability.

Prior to joining ZOLL in 2013, Knudsen held leadership positions in international sales, marketing, and manufacturing partnerships at Covidien (now Medtronic), Aspect Medical Systems, and LeMaitre Vascular. He has an MBA from the Thunderbird School of Global Management and a bachelor’s degree from Boston College.

Rennert was named CEO of ZOLL in 2016, after serving as President of the company’s largest business unit for eight years. Under Rennert’s leadership as CEO, ZOLL expanded its reach as a global leader in external defibrillation, pioneered novel solutions for patients with serious cardiopulmonary and respiratory conditions, and significantly broadened its portfolio of products.

About ZOLL
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.

About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world’s challenges through its three business sectors of Healthcare, Homes, and Material. Its healthcare operations include devices and systems for critical care, products and services for the manufacture of biotherapeutics, and a growing portfolio of specialty pharmaceuticals. For more information, visit www.asahi-kasei.com.

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.

Copyright © 2026 ZOLL Medical Corporation. All rights reserved. ZOLL is a registered trademark of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.

Contacts

Matt Hogan
ZOLL
978-805-6561
[email protected]

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0007115
$0.0007115$0.0007115
-7.04%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Share
BitcoinEthereumNews2025/09/18 03:26
VectorUSA Achieves Fortinet’s Engage Preferred Services Partner Designation

VectorUSA Achieves Fortinet’s Engage Preferred Services Partner Designation

TORRANCE, Calif., Feb. 3, 2026 /PRNewswire/ — VectorUSA, a trusted technology solutions provider, specializes in delivering integrated IT, security, and infrastructure
Share
AI Journal2026/02/05 00:02
Top Solana Treasury Firm Forward Industries Unveils $4 Billion Capital Raise To Buy More SOL ⋆ ZyCrypto

Top Solana Treasury Firm Forward Industries Unveils $4 Billion Capital Raise To Buy More SOL ⋆ ZyCrypto

The post Top Solana Treasury Firm Forward Industries Unveils $4 Billion Capital Raise To Buy More SOL ⋆ ZyCrypto appeared on BitcoinEthereumNews.com. Advertisement &nbsp &nbsp Forward Industries, the largest publicly traded Solana treasury company, has filed a $4 billion at-the-market (ATM) equity offering program with the U.S. SEC  to raise more capital for additional SOL accumulation. Forward Strategies Doubles Down On Solana Strategy In a Wednesday press release, Forward Industries revealed that the 4 billion ATM equity offering program will allow the company to issue and sell common stock via Cantor Fitzgerald under a sales agreement dated Sept. 16, 2025. Forward said proceeds will go toward “general corporate purposes,” including the pursuit of its Solana balance sheet and purchases of income-generating assets. The sales of the shares are covered by an automatic shelf registration statement filed with the US Securities and Exchange Commission that is already effective – meaning the shares will be tradable once they’re sold. An automatic shelf registration allows certain publicly listed companies to raise capital with flexibility swiftly.  Kyle Samani, Forward’s chairman, astutely described the ATM offering as “a flexible and efficient mechanism” to raise and deploy capital for the company’s Solana strategy and bolster its balance sheet.  Advertisement &nbsp Though the maximum amount is listed as $4 billion, the firm indicated that sales may or may not occur depending on existing market conditions. “The ATM Program enhances our ability to continue scaling that position, strengthen our balance sheet, and pursue growth initiatives in alignment with our long-term vision,” Samani said. Forward Industries kicked off its Solana treasury strategy on Sept. 8. The Wednesday S-3 form follows Forward’s $1.65 billion private investment in public equity that closed last week, led by crypto heavyweights like Galaxy Digital, Jump Crypto, and Multicoin Capital. The company started deploying that capital this week, announcing it snatched up 6.8 million SOL for approximately $1.58 billion at an average price of $232…
Share
BitcoinEthereumNews2025/09/18 03:42